These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12937319)

  • 21. [Relationship between heart and kidney].
    Ito S
    Nihon Naika Gakkai Zasshi; 2006 May; 95(5):952-8. PubMed ID: 16774075
    [No Abstract]   [Full Text] [Related]  

  • 22. [Profibrotic effects of aldosterone].
    Van Den Meiracker AH; Huizenga AT; Boomsma F
    Ned Tijdschr Geneeskd; 2004 Jul; 148(31):1532-6. PubMed ID: 15366722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
    Bertocchio JP; Warnock DG; Jaisser F
    Kidney Int; 2011 May; 79(10):1051-60. PubMed ID: 21412221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Participation of the mineralocorticoid receptor in cardiac and vascular remodeling.
    Fiebeler A; Haller H
    Nephron Physiol; 2003; 94(3):p47-50. PubMed ID: 12902615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone action in the heart.
    Firsov D; Muller OG
    Pflugers Arch; 2003 Jun; 446(3):328-33. PubMed ID: 12733077
    [No Abstract]   [Full Text] [Related]  

  • 26. Aldosterone antagonism in chronic kidney disease.
    Ponda MP; Hostetter TH
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):668-77. PubMed ID: 17699271
    [No Abstract]   [Full Text] [Related]  

  • 27. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
    Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
    Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiological implications of hypoxia in human diseases.
    Chen PS; Chiu WT; Hsu PL; Lin SC; Peng IC; Wang CY; Tsai SJ
    J Biomed Sci; 2020 May; 27(1):63. PubMed ID: 32389123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nongenomic actions of aldosterone on the renal tubule.
    Good DW
    Hypertension; 2007 Apr; 49(4):728-39. PubMed ID: 17309947
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 32. [The pathogenetic bases of cardiorenal syndrome].
    Beloglazova IP; Mogutova PA; Poteshkina NG
    Ter Arkh; 2012; 84(9):97-103. PubMed ID: 23091862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osborne-Mendel rats simultaneously develop cardiac and renal dysfunction, left atrial thrombosis, peripheral artery occlusion, and ascending aortic dissection.
    Asahina M; Matsumoto H; Yasuhara Y; Suzuki N; Takami R; Takeyama M; Tozawa R
    Biochem Biophys Res Commun; 2017 Apr; 485(2):550-555. PubMed ID: 28088517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of aldosterone in the remnant kidney model in the rat.
    Greene EL; Kren S; Hostetter TH
    J Clin Invest; 1996 Aug; 98(4):1063-8. PubMed ID: 8770880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aldosterone and renal injury].
    Nishiyama A; Abe Y
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):101-9. PubMed ID: 15277728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac assessment in chronic kidney disease.
    McIntyre CW; Odudu A; Eldehni MT
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):501-6. PubMed ID: 19724223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal adaptation to the failing heart. Understanding the cascade of responses.
    Riley DJ; Weir M; Bakris GL
    Postgrad Med; 1994 Jun; 95(8):141-6, 149-50. PubMed ID: 8202419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mineralocorticoid receptor: an update].
    Nagase M
    Nihon Rinsho; 2012 Sep; 70(9):1504-9. PubMed ID: 23012795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone is a major factor in the progression of renal disease.
    Ibrahim HN; Rosenberg ME; Greene EL; Kren S; Hostetter TH
    Kidney Int Suppl; 1997 Dec; 63():S115-9. PubMed ID: 9407437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The physiopathological aspects of the atrial natriuretic factor].
    Agen C; Bernardini N; Blandizzi C; Danesi R; Del Tacca M
    Minerva Med; 1992 Apr; 83(4):169-80. PubMed ID: 1315427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.